Cancer Immunotherapy

New Tumor Antigen Dubbed CAMEL

Published in Cancer Weekly, August 16th, 1999

CAMEL, a new tumor antigen, has been discovered and may be a target for anticancer immunotherapy strategies.

C.A. Aarnoudse and colleagues from the University of Leiden, The Netherlands, discovered a new tumor antigen which they dubbed CAMEL, which is short for CTL-recognized antigen on melanoma. The finding was reported in a recent issue of the International Journal of Cancer ("Interleukin-2-Induced, Melanoma-Specific T Cells Recognize Camel, An Unexpected Translation Product of LAGE-1," International Journal of Cancer, July 30, 1999;82(3):442-448).

"Melanoma-specific cytotoxic T lymphocytes (CTLs) were induced by in vitro stimulation of peripheral...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-08-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry